China-based Luye Pharma Group has entered into an agreement with South Korea's Myung In Pharm, granting the latter the exclusive rights to commercialise Rivastigmine Twice Weekly Transdermal Patch in South Korea. Developed by Luye Pharma, this drug is used to treat mild to moderate dementia associated with Alzheimer's disease (AD).
China-based Luye Pharma Group has entered an agreement with Duopharma Marketing Sdn Bhd, a wholly-owned subsidiary of Duopharma Biotech Berhad (Duopharma Biotech), which grants the latter exclusive marketing and distribution rights to a cholesterol management product in Malaysia. nnDeveloped by Luye Pharma, the product is a traditional Chinese medicine made by using modern technology to ferment special red yeast rice, a natural alternative for cholesterol management. nnThrough this partnership, Luye Pharma will be able to leverage Duopharma Biotech's long-term expertise in the cardiovascular therapeutic field, both in terms of its excellent promotion in academic and extensive distribution network throughout clinics and hospitals, further expanding the accessibility of the product in Malaysia. The two companies expect that the product will grow at a compound annual growth rate of double digits in the local market over the next 10 years.
The US Food and Drug Administration (FDA) has approved Luye Pharma Group’s Rykindo (risperidone) as an extended-release injectable suspension to treat schizophrenia in adult patients.
Luye Pharma Group, with R&D centres in China, the US and Europe, has entered a distribution and marketing partnership with ICI Pakistan, a leading manufacturing and trading company based in Pakistan.
Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.
Luye Pharma Group today announced that the phase I clinical trial for LY-CovMab, an innovative antibody for the treatment of COVID-19, has been completed in China, with good results in safety and tolerance observed. LY-CovMab was developed by Boan Biotech, a holding subsidiary of the Group. Phase II clinical studies for the antibody are soon to start in China the U.S. and Europe, accelerating the R&D process in global markets to provide an effective treatment to patients as early as possible.
BASEL, Switzerland, Feb. 18, 2021 /PRNewswire/ -- Luye Pharma Group announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Towa Pharmaceutical Co., Ltd. (Towa), the terms of which grant Towa exclusive rights to the development and commercialization of Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) in Japan.
Luye Pharma’s Antidepressant Drug LY03005 Completes Primary Endpoint Observation for a Phase III Clinical Trial in China
Luye Pharma’s Antidepressant Drug LY03005 Completes Primary Endpoint Observation for a Phase III Clinical Trial in China
Luye Pharma Group announced that Denosumab Injection (LY01011), a biosimilar of Xgeva® developed by Shandong Boan Biotechnology Co. Ltd. (Boan Biotech), a subsidiary of the Group, has started a comparative clinical study (a Phase III clinical study) in China. The clinical trials of the drug in Europe and the U.S. are also under way and progressing well.